Nurse-initiated protocols in the emergency department management of pediatric oncology patients with fever and suspected neutropenia: a scoping review protocol
Objective: To provide an overview of the evidence for nurse-initiated protocol in the emergency management of pediatric oncology patients with fever and neutropenia is suspected.
Introduction: febrile neutropenia in pediatric oncology patients pose a significant burden of increased morbidity and mortality. Prompt, efficient emergency care and rapid administration of antibiotics within 60 minutes of presentation to the hospital is required to prevent clinical deterioration and reduce the rate of entry of intensive care and death.
efficient emergency department care delivery is influenced by modern challenges, such as increasing user demand, limited resources, and lack of flow. In response to this, in order to expedite the provision of care, practice guidelines have been developed to include nurse initiated protocols that guide nurses to initiate investigations that have been specifically and intervention for patients meet certain criteria. Febrile neutropenic pediatric patients may be certain groups that can benefit from nurse-initiated protocol because of the critical nature of the required treatment time.
Inclusion criteria: Review of scoping will consider the literature that reports the nurse initiated protocols in the management of pediatric oncology febrile neutropenia in patients suspected of emergency department setting. Methods: JBI methodology for scoping review will guide the review process. English literature from 2000 to the present will be sought in Embase, Medline, Scopus, Emcare, CINAHL Plus and gray literature in Google Scholar, Open Gray, and global Theses. critical assessment will be performed. Tabular summary and accompanying narrative will present information extracted in tune with this review evidence and objective questions. In recognition of the increasing incidence and mortality of cancer in low and medium settings resources, as well as the increasingly international profile membership, ASCO has prioritized efforts to increase its involvement on a global level.
Among the recommendations in the 2016 report include Global Oncology Leadership Task Force ASCO ASCO is that the Board of Directors should promote the recognition of global oncology academic field. The report recommends that the ASCO could serve a role in the transition of the global oncology field largely informal voluntary activity to a more formal discipline with a strong research and training components are well defined. As a result of this recommendation, in 2017, ASCO shaping global Oncology Academic Task Force (AGOTF) to guide the ASCO contribution to inaugurate global oncology field.
Patient perception Telehealth Service for Breast and Gynecologic Oncology Care for Pandemic COVID-19: Survey based study A Single Center
Before the coronavirus disease in 2019 (COVID-19) pandemic, telehealth is rarely used for oncology care in the metropolitan area. New York City based breast outpatient clinics / major gynecological cancer we are given a 18-question survey to patients from March to June 2020, to assess the perception of the usefulness of telehealth medicine. Of the 622 patients, 215 (35%) completed the survey, and of the 215 respondents, 74 (35%) have participated in telehealth visits. We evaluated the use of telehealth services using a validated Technology Service User Acceptance Questionnaire.
Sixty-eight patients (92%) reported that telehealth services save them time, 54 (73%) reported telehealth improved access to treatment, and 58 (82%) reported telehealth improve their health. Overall, 67 (92%) of the patients said they were satisfied with the use of telehealth services for oncology care during the 19th COVID pandemic. telehealth services should be carefully adopted as an adjunct in the clinical care of patients with cancer.
Nurse-initiated protocols in the emergency department management of pediatric oncology patients with fever and suspected neutropenia: a scoping review protocol
glioblastoma post-operative imaging in the neuro-oncology: current UK practice (GIN CUP study)
Purpose: MRI remains the preferred imaging investigation for glioblastoma. neuroimaging appropriate and timely follow-up period was considered important in making management decisions. There is a shortage of evidence-based information on the current UK, European and international guidelines on the timing and type of neuroimaging after surgical treatment of early nerves optimal. The study assessed the current imaging practice between central neuro-oncology UK, so as to provide basic data and inform future practice.
Methods: Leading neuro-oncology, neuroradiologist and neurosurgeon of any UK neuro-oncology centers were invited to complete an online survey. Participants were asked about current practices and ideal imaging after initial treatment.
Results: Ninety-two participants from around 31 neuro-oncology centers completed the survey (response rate of 100%). Most centers routinely performed early postoperative MRI (87%, 27/31), while only a third of pre-radiotherapy MRI (32%, 10/31). Number and timing of routine scans performed during adjuvant TMZ treatment varies between centers. At the end of the adjuvant, most centers do MRI (71%, 22/31), followed by monitoring scan 3 monthly intervals (81%, 25/31). Additional short-interval imaging is done in cases which may pseudoprogression in most centers (71%, 22/31). Routine use of advanced imaging is rare; However, the addition of advanced sequence is the most popular suggestions for ideal imaging practice, followed by a time change EPMRI.
Description: A polyclonal antibody against TAT. Recognizes TAT from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000
Description: A polyclonal antibody against TAT. Recognizes TAT from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF; Recommended dilution: WB:1:500-1:5000, IF:1:50-1:200
Description: A polyclonal antibody against TAT. Recognizes TAT from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100
Description: This nuclear gene encodes a mitochondrial protein tyrosine aminotransferase which is present in the liver and catalyzes the conversion of L-tyrosine into p-hydroxyphenylpyruvate. Mutations in this gene cause tyrosinemia (type II, Richner-Hanhart syndrome), a disorder accompanied by major skin and corneal lesions, with possible mental retardation. A regulator gene for tyrosine aminotransferase is X-linked.
Description: A polyclonal antibody for detection of TAT from Human, Mouse, Rat. This TAT antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human TAT
Description: A polyclonal antibody for detection of TAT from Human, Mouse, Rat. This TAT antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human TAT
Description: A polyclonal antibody for detection of TAT from Human, Mouse, Rat. This TAT antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human TAT
Description: A competitive inhibition quantitative ELISA assay kit for detection of Canine C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Canine C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A polyclonal antibody against TAT. Recognizes TAT from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against TAT. Recognizes TAT from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Conclusion: Variations in neuroimaging practice there after the initial treatment of glioblastoma in the United Kingdom. Multicenter, longitudinal, prospective trial is needed to determine the optimal imaging schedule for the assessment.
